Uptravi

Active Ingredient(s): Selexipag
FDA Approved: * December 21, 2015
Pharm Company: * ACTELION PHARMS LTD
Category: Blood Pressure

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Uptravi Overview

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[1] ACT-333679 or MRE-269, the active metabolite of selexipag Contents 1 Contraindications 2 Adverse effects 3 History 4 See also 5 References Contraindications...

Read more Uptravi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Selexipag

Recent Uptravi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Uptravi: (8 results)

Sorted by National Drug Code

• 66215-602 Uptravi 200 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-604 Uptravi 400 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-606 Uptravi 600 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-608 Uptravi 800 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-610 Uptravi 1000 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-612 Uptravi 1200 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-614 Uptravi 1400 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.
• 66215-616 Uptravi 1600 ug/1 Oral Tablet, Coated by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Selexipag or a similar ingredient: (1 result)

• SELEXIPAG